Reagents Business Drives up GenMark's Q1 Revenues 185 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that revenues for the first quarter increased 185 percent year over year, led by reagents revenues.

For the period ended March 31, total revenues increased to $2.2 million from $758,000, as product revenues rose to $2.1 million from $693,000 while license and other revenues dropped to $39,000 from $65,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.